neuropharmacy masterclass
play

Neuropharmacy Masterclass Case Studies Jan 19 Case 1 29 yr old - PowerPoint PPT Presentation

Neuropharmacy Masterclass Case Studies Jan 19 Case 1 29 yr old female RRMS diagnosed 10yrs ago Rebif started 2008 Jan 2016 - experiencing injection fatigue What are her options ? dimethyl fumarate or teriflunomide Case 1


  1. Neuropharmacy Masterclass Case Studies Jan 19

  2. Case 1 • 29 yr old female • RRMS diagnosed 10yrs ago • Rebif started 2008 • Jan 2016 - experiencing injection fatigue • What are her options ? – dimethyl fumarate or teriflunomide

  3. Case 1 (cont...) • Switched to DMF • Jan 2016 – Sept 17 - stable , no relapses • Lymphocyte count on routine monitoring : Date Lymphocyte count Mar 2016 – Dec 16 0.8 – 1.0 Dec 16 0.8 Mar 17 0.6 June 17 0.5 Sept 17 0.4

  4. Case 1 (cont…) What action do you recommend? – Continue – Continue with increased monitoring – Withhold until counts rise – Stop Date Lymphocyte count Sept 17 0.4 Oct 17 0.5 Nov 17 0.4

  5. Case 1 (cont..) • Drug stopped Nov 17 • What are her DMT options ? .....Only teriflunomide • When do we start teriflunomide ? – Lymphocyte count? – >0.8

  6. Case 2 • 32yr old male, RRMS • Diagnosed RES MS 2014. Very active scan • Alemtuzumab jan 2015 & jan 2016 • Jan 2017 – relapse – leg weakness • Options? – Steroids only & wait – Switch to another DMT? – 3 rd dose alemtuzumab

  7. • Brought to MDT to discuss options: • Is a single relapse 6m after year 2 treatment failure? - alemtuzumab not working – switch - 1 relapse in 3 years – working , 3 rd dose • Switch options? – Cladribine – Ocrelizumab?

  8. Case 3 • 40yr old male • Had 1 st course alemtuzumab Jan 17 • Due for year 2, Jan 18 • Screening bloods show : Date T4 T3 TSH

  9. Case 4 • 41yr old male • RRMS diagnosed 2014 • 2014-2016 – dimethyl fumarate • July 2016 , relapse & new lesion on MRI • Options? – fingolimod – alemtuzumab – cladribine

  10. Case 4 … • Patient selects fingolimod • Starts Sept 16 • Lymphocyte counts : Date Lymphocyte count

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend